These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8500301)

  • 1. A computer program for designing clinical trials with arbitrary survival curves and group sequential testing.
    Halpern J; Brown BW
    Control Clin Trials; 1993 Apr; 14(2):109-22. PubMed ID: 8500301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test.
    Halpern J; Brown BW
    Control Clin Trials; 1987 Sep; 8(3):177-89. PubMed ID: 3665521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing a primary and a secondary endpoint in a group sequential design.
    Tamhane AC; Mehta CR; Liu L
    Biometrics; 2010 Dec; 66(4):1174-84. PubMed ID: 20337631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks.
    Tamhane AC; Gou J; Jennison C; Mehta CR; Curto T
    Biometrics; 2018 Mar; 74(1):40-48. PubMed ID: 28589692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group sequential design for historical control trials using error spending functions.
    Wu J; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):351-363. PubMed ID: 31718458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance.
    Li H; Wang J; Luo X; Grechko J; Jennison C
    Biom J; 2018 Sep; 60(5):893-902. PubMed ID: 29876964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternatives to the standard Fleming, Harrington, and O'Brien futility boundary.
    Anderson JR; High R
    Clin Trials; 2011 Jun; 8(3):270-6. PubMed ID: 21441286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group sequential Holm and Hochberg procedures.
    Tamhane AC; Xi D; Gou J
    Stat Med; 2021 Oct; 40(24):5333-5350. PubMed ID: 34636081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated significance tests on accumulating survival data.
    Skovlund E
    J Clin Epidemiol; 1999 Nov; 52(11):1083-8. PubMed ID: 10527002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
    Sebille V; Bellissant E
    Clin Sci (Lond); 2000 May; 98(5):569-78. PubMed ID: 10781388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional power for arbitrary survival curves to decide whether to extend a clinical trial.
    Henderson WG; Fisher SG; Weber L; Hammermeister KE; Sethi G
    Control Clin Trials; 1991 Apr; 12(2):304-13. PubMed ID: 1645642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous sequential monitoring of efficacy and safety led to masking of effects.
    van Eekelen R; de Hoop E; van der Tweel I
    J Clin Epidemiol; 2016 Aug; 76():155-65. PubMed ID: 26944293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing complex group sequential survival trials.
    Lakatos E
    Stat Med; 2002 Jul; 21(14):1969-89. PubMed ID: 12111882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of group sequential logrank tests in a maximum duration trial.
    Lan KK; Lachin JM
    Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.